Even though a clear relationship between GH therapy and brain tumor onset has not been demonstrated, it is recommended that physicians should be aware of the possibility of increased neoplasia risk and that they should make judicious use of GH therapy for patients with tumor-predisposition syndromes such as NS [44]. This evidence concerns the gene GH1 and brain neoplasm.